NCT Number: NCT00219570
Dalacin-T Gel Post Approval Study
To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.
Looking for future studies?
Notify MeKey information
Conditions
Age range
13 year–35 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Acne vulgaris patients found by a investigator to have at least 10 inflammatory lesions (papules, pustules) on a portion of either a cheeks or the forehead, with an inflammation severity of moderate or worse.
Exclusion criteria
- Patients with, for example, acne elastosis, steroidal acne, necrotizing acne, or occupational acne.
Treatment and study plan
nadifloxacin
DrugPrimary outcomes
-
To verify the non-inferiority to Acuatim cream of Dalacin T Gel in terms of the percent reduction in the inflammatory lesion count (the assessments of investigator) at Treatment Week 4 or EOT (discontinuation)
Secondary outcomes
-
To verify the non-inferiority to Acuatim cream of Dalacin T Gel in terms of the percent reduction in the inflammatory lesion count (the assessments of the Data Review Committee based on photographs) at Treatment Week 4 or EOT (discontinuation) According
Sponsors and collaborators
Lead sponsor
Pfizer
Industry
Collaborators
- Acronet
- Bellsystem24 , Inc.
- Mitsubishi Kagaku Bio-Clinical Laboratories, inc
- Parexel
- SACT INTERNATIONAL Co., LTD.
- SATO Pharmaceutical Co., Ltd.
Registry information
Official study title
Phase IV Clinical Study Of Clindamycin Phosphate Topical Gel In The Treatment Of Acne Vulgaris
Important dates
- Study start
- 2005
- Study completion
- 2005
- First posted
- Sep 22, 2005
- Registry last updated
- May 11, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
NCT05080764
Acne Vulgaris, Acneiform Eruptions
Fountain Valley, California, United States
View Trial DetailsAI-Generated Acne Vulgaris Learning Material Study
NCT07652112
Acne Vulgaris, Acneiform Eruptions
Kayseri, Turkey (Türkiye)
View Trial DetailsA Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients
NCT06415279
Acne Vulgaris, Acneiform Eruptions
High Point, North Carolina, United States
View Trial DetailsRandomized, Triple-Blind, Vehicle-Controlled Trial of Topical Dapsone Gel 7.5% in Patients With Acne Vulgaris
NCT07244887
Acne Vulgaris, Acneiform Eruptions
Istanbul, Turkey (Türkiye)
View Trial Details